Checks How Common Fatty Pancreas Is in Pancreatic Cysts and Cancer
Studies whether fatty pancreas is more common in pancreatic cysts and cancer.
Plain-language title generated from the registry record
Registry title: Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma
Key facts
- Where
- Bucharest, RomaniaSee the site
Where in Romania
- Prof Dr Agrippa Ionescu; Clinical Emergency HospitalBucharest, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Carol Davila University of Medicine and Pharmacy
- Trial code
- NCT06867172
- Record updated
- 10 March 2025
- Original description
Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).Read full original descriptionShow less
The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study
Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).
The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk.
The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Inclusion: Age 18 or older; Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).
Exclusion: Pancreatic surgery at baseline imaging in our department; No evidence of written informed consent; Patients with contraindications for endoscopy due to comorbidities; Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary); Acute pancreatitis at baseline imaging; Splenectomy; Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women.